At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Opioid Antagonist Activity in Humans
In Brief
A Phase 2 clinical trial evaluating Buprenorphine, Morphine, and 1 other intervention for Opioid-related Disorders. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is a residential study that looks at the effects of buprenorphine in persons who abuse but are not dependent on opioids. Animal studies show that very high doses of buprenorphine produce less effects than mid-range doses. This suggests that buprenorphine can be a very safe medication. However, no studies in humans have tested higher doses in a similar way. The goal of this study is to show the effects of single doses of buprenorphine, across a range of doses, in persons who are not physically dependent on opioids (but do abuse opioids).
Study Details
Timeline
Interventions
Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
Intramuscular; double blind; once per week